{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:14:31Z","timestamp":1793304871593,"version":"4.5.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,6,1]]},"DOI":"10.1001\/jamaoncol.2020.0750","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T13:27:46Z","timestamp":1588253266000},"page":"872","source":"Crossref","is-referenced-by-count":167,"title":["Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma"],"prefix":"10.1001","volume":"6","author":[{"given":"Paul J.","family":"Br\u00f6ckelmann","sequence":"first","affiliation":[{"name":"Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Cologne, Germany"},{"name":"German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Goergen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Cologne, Germany"},{"name":"German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[{"name":"Klinikum Rechts der Isar der TU M\u00fcnchen, Internal Medicine III, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Meissner","sequence":"additional","affiliation":[{"name":"Medicine V, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Ordemann","sequence":"additional","affiliation":[{"name":"University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa V.","family":"Halbsguth","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine II, Goethe University Hospital Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Sasse","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Cologne, Germany"},{"name":"German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"S\u00f6kler","sequence":"additional","affiliation":[{"name":"University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kerkhoff","sequence":"additional","affiliation":[{"name":"Medizinische Klinik A, University Hospital Muenster, Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mathas","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Tumor Immunology, Charit\u00e9-Universit\u00e4tsmedizin Berlin and Max-Delbr\u00fcck-Center for Molecular Medicine, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"H\u00fcttmann","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital of Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bormann","sequence":"additional","affiliation":[{"name":"Medical Department I, Klinikum Bremen-Mitte, Bremen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Mettler","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Cologne, Germany"},{"name":"German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Cologne, Germany"},{"name":"German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Baues","sequence":"additional","affiliation":[{"name":"German Hodgkin Study Group, Cologne, Germany"},{"name":"Department of Radiooncology and Cyberknife Center, Faculty of Medicine, University Hospital Cologne, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Kobe","sequence":"additional","affiliation":[{"name":"German Hodgkin Study Group, Cologne, Germany"},{"name":"Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Cologne, Germany"},{"name":"German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Cologne, Germany"},{"name":"German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"coi200012r1","doi-asserted-by":"publisher","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol"},{"issue":"18","key":"coi200012r2","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials.","volume":"35","author":"Sasse","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi200012r3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J Clin Oncol"},{"issue":"16","key":"coi200012r4","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial.","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi200012r5","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S1470-2045(16)30093-6","article-title":"Cancer-related fatigue in patients with and survivors of Hodgkin\u2019s lymphoma: a longitudinal study of the German Hodgkin Study Group.","volume":"17","author":"Kreissl","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"coi200012r6","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/annonc\/mdr575","article-title":"Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial.","volume":"23","author":"Behringer","year":"2012","journal-title":"Ann Oncol"},{"issue":"9","key":"coi200012r7","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S1470-2045(16)30215-7","article-title":"Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin\u2019s lymphoma: an analysis from the St Jude Lifetime Cohort Study.","volume":"17","author":"Bhakta","year":"2016","journal-title":"Lancet Oncol"},{"issue":"26","key":"coi200012r8","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma.","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"coi200012r9","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome.","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi200012r10","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"22","key":"coi200012r11","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"issue":"16","key":"coi200012r12","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL.","volume":"131","author":"Vari","year":"2018","journal-title":"Blood"},{"issue":"9","key":"coi200012r13","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"coi200012r14","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"14","key":"coi200012r15","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial.","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi200012r16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/2326-6066.CIR-16-0197","article-title":"Immunological mechanisms underneath the efficacy of cancer therapy.","volume":"4","author":"Galluzzi","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"9976","key":"coi200012r17","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"coi200012r18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/bjh.2018.181.issue-6","article-title":"Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin lymphoma patients treated with PD1 inhibition.","volume":"181","author":"Hude","year":"2018","journal-title":"Br J Haematol"},{"issue":"36","key":"coi200012r19","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1200\/JCO.19.00985","article-title":"Pretreatment vitamin D deficiency is associated with impaired progression-free and overall survival in Hodgkin lymphoma.","volume":"37","author":"Borchmann","year":"2019","journal-title":"J Clin Oncol"},{"issue":"23","key":"coi200012r20","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study.","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"key":"coi200012r21","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1182\/blood-2018-99-113836","article-title":"A phase II study of sequential pembrolizumab (PEM) followed by AVD for frontline treatment of classical Hodgkin lymphoma (CHL): quantifying response following PEM monotherapy with FDG-PET-derived metabolic tumor volume and total lesion glycolysis.","volume":"132","author":"Savas","year":"2018","journal-title":"Blood"},{"issue":"21","key":"coi200012r22","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"3","key":"coi200012r23","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"coi200012r24","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1080\/10428194.2018.1540781","article-title":"Survivors\u2019 perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.","volume":"60","author":"Kreissl","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"coi200012r25","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","article-title":"Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2765292\/jamaoncology_brckelmann_2020_oi_200012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T12:45:56Z","timestamp":1591879556000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2765292"}},"subtitle":["The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial"],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.0750","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}